- Home
- BRNS vs ANEB Comparison
BRNS vs ANEB Comparison
Compare BRNS & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- ANEB
- Stock Information
- Founded
- BRNS 2016
- ANEB 2020
- Country
- BRNS United Kingdom
- ANEB United States
- Employees
- BRNS N/A
- ANEB N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- ANEB Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- ANEB Health Care
- Exchange
- BRNS Nasdaq
- ANEB Nasdaq
- Market Cap
- BRNS 55.9M
- ANEB 111.8M
- IPO Year
- BRNS 2021
- ANEB 2021
- Fundamental
- Price
- BRNS $1.32
- ANEB $2.75
- Analyst Decision
- BRNS Strong Buy
- ANEB Buy
- Analyst Count
- BRNS 1
- ANEB 2
- Target Price
- BRNS $3.00
- ANEB $8.00
- AVG Volume (30 Days)
- BRNS 253.1K
- ANEB 25.7K
- Earning Date
- BRNS 11-06-2025
- ANEB 11-12-2025
- Dividend Yield
- BRNS N/A
- ANEB N/A
- EPS Growth
- BRNS N/A
- ANEB N/A
- EPS
- BRNS N/A
- ANEB N/A
- Revenue
- BRNS $14,969,000.00
- ANEB N/A
- Revenue This Year
- BRNS N/A
- ANEB N/A
- Revenue Next Year
- BRNS N/A
- ANEB N/A
- P/E Ratio
- BRNS N/A
- ANEB N/A
- Revenue Growth
- BRNS 1766.46
- ANEB N/A
- 52 Week Low
- BRNS $0.64
- ANEB $0.80
- 52 Week High
- BRNS $2.92
- ANEB $3.42
- Technical
- Relative Strength Index (RSI)
- BRNS 50.56
- ANEB 62.06
- Support Level
- BRNS $1.23
- ANEB $2.50
- Resistance Level
- BRNS $1.50
- ANEB $2.76
- Average True Range (ATR)
- BRNS 0.13
- ANEB 0.13
- MACD
- BRNS -0.02
- ANEB 0.04
- Stochastic Oscillator
- BRNS 22.22
- ANEB 79.03
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.